(Q47981636)

English

Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report

scientific article published on 18 July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

neuroendocrine tumor

1 reference

based on heuristic

inferred from title

interstitial lung disease

1 reference

based on heuristic

inferred from title

Motohiro Kojima

3

object named as

Motohiro Kojima

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

author name string

Yusuke Nakayama

1

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

Masafumi Ikeda

2

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

Koichi Goto

4

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

Miyuki Hara

5

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

Hiroyuki Okuyama

6

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

Hideaki Takahashi

7

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

Izumi Ohno

8

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

Satoshi Shimizu

9

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

Shuichi Mitsunaga

10

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

Takuji Okusaka

11

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

publication date

18 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

59

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

1

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

74-78

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1159%2F000351103

21 January 2018

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1159%2F000351103

21 January 2018

Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1.

1 reference

https://api.crossref.org/works/10.1159%2F000351103

21 January 2018

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000351103

21 January 2018

Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001).

1 reference

https://api.crossref.org/works/10.1159%2F000351103

21 January 2018

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

1 reference

https://api.crossref.org/works/10.1159%2F000351103

21 January 2018

Pulmonary toxicities from targeted therapies: a review

1 reference

https://api.crossref.org/works/10.1159%2F000351103

21 January 2018

Interstitial pneumonitis after treatment with pemetrexed: a rare event?

1 reference

https://api.crossref.org/works/10.1159%2F000351103

21 January 2018

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1159%2F000351103

21 January 2018

Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases

1 reference

https://api.crossref.org/works/10.1159%2F000351103

21 January 2018

Circulating KL-6 levels in patients with drug induced pneumonitis.

1 reference

https://api.crossref.org/works/10.1159%2F000351103

21 January 2018

Identifiers

10.1159/000351103

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

release_rournkrigzcvjhwnysgyx7lxxe

1 reference

https://api.fatcat.wiki/v0/release/rournkrigzcvjhwnysgyx7lxxe

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/23867634

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47981636&oldid=2180549981"